Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05590962 · ClinicalTrials.gov registry record · NA
Predictive Analytics and Behavioral Nudges to Improve Palliative Care in Advanced Cancer
A NA study, sponsored by Abramson Cancer Center at Penn Medicine.
- Completed
- Registry status
- NA
- Development phase
- 562
- Enrollment target
NCT05590962: Completed NA study, sponsored by Abramson Cancer Center at Penn Medicine.
NCT05590962 is a NA study that has completed, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 562 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (60% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05590962, a NA study, has completed, sponsored by Abramson Cancer Center at Penn Medicine.
- COMPLETED
- Registry status
- NA
- Development phase
- 562 participants
- Enrollment target
Study Summary
Patients with advanced cancer suffer from high symptom burden and aggressive end-of-life care. Early specialty palliative care is an evidence-based practice that improves symptom burden, quality of life, and survival in advanced cancer. However, over half of patients with advanced cancer die before receiving palliative care. Clinician-level biases and suboptimal identification of high-risk patients are major barriers to palliative care uptake. In this 2-arm pragmatic clinical trial, the investigators will randomize practices within a large community oncology network to receive an intervention consisting of algorithm-based default palliative care referrals. The investigators will study the impact of such an intervention on palliative care utilization and end-of-life outcomes.
Primary Outcome
Completed palliative care visit within 3 months among high-risk patients with stage III and IV lung and non-colorectal GI malignancies
Interventions
- OTHER EHR Nudge
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 562 participants |
| Start Date | 2022-11-09 |
| Est. Completion | 2023-10-03 |
| Phase | NA |
What the finished NCT05590962 record still lists
NCT05590962 is an interventional study that assigns participants to a tested intervention. The registered 562 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (60% lower).
The record links to 0 conditions, and to 1 intervention - of which EHR Nudge is the first listed.
NCT05590962 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05590962 about?
NCT05590962 is a clinical study titled "Predictive Analytics and Behavioral Nudges to Improve Palliative Care in Advanced Cancer". Patients with advanced cancer suffer from high symptom burden and aggressive end-of-life care. Early specialty palliative care is an evidence-based practice that improves symptom burden, quality of life, and survival in advanced cancer. However, over half of patients with advanced cancer die before ...
What is the current status of trial NCT05590962?
This trial is currently completed. It is a NA study. The enrollment target is 562 participants. The study started on 2022-11-09. Estimated completion is 2023-10-03.
What interventions are being tested in trial NCT05590962?
The interventions under investigation include: EHR Nudge (OTHER).
Who is sponsoring clinical trial NCT05590962?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05590962's enrollment target sits among peer trials
562 181st of 2000 higher than 1,820 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07007065 · 561 participants · Phase 3
Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD)
- NCT06146725 · 564 participants
The RESBIOP-study: Resection Versus Biopsy in High-grade Glioma Patients (ENCRAM 2202)
- NCT06188520 · 564 participants · Phase 1
A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors
- NCT06628453 · 564 participants · NA
CGM for Management of Type 2 Diabetes in Pregnancy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI